GlassScriptPhysician profile
Aaron Langford
NPI 1669809471
$5,848.56
in general payments reported to CMS, 2019-2025
20 companies · $789 in 2025
The $789 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,153 · 2022: $658 · 2023: $1,437 · 2024: $812 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,038.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,427.85 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $941.77 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $597.47 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $491.42 | 2021-2025 | Rexulti |
| Lundbeck LLC | $393.19 | 2021-2025 | Rexulti |
| Corium, LLC | $303.23 | 2023-2024 | Azstarys |
| Bausch Health US, LLC | $286.76 | 2021-2025 | Aplenzin, Wellbutrin |
| Alkermes, INC. | $264.66 | 2021-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $246.41 | 2023-2025 | Austedo Xr, Austedo Xr |
| Tris Pharma INC | $188.34 | 2023-2024 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $178.34 | 2021 | |
| Neos Therapeutics, LP | $162.69 | 2021-2024 | Adzenys Xr-Odt |
| Janssen Pharmaceuticals, INC | $126.71 | 2021-2025 | Spravato |
| Jazz Pharmaceuticals INC. | $60.58 | 2021 | |
| Axsome Therapeutics, INC. | $58.31 | 2024 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $37.96 | 2021 | |
| Idorsia Pharmaceuticals US INC | $24.16 | 2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $20.98 | 2025 | Qelbree |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.97 | 2021 | |
| Avion Pharmaceuticals | $17.76 | 2024 | Methylphenidate Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Langford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.